参考文献/References:
[1] MARTIN R M, BACHMAN M. Colonization,infection, and the accessory genome of Klebsiella pneumoniae [J]. Frontiers in Cellular and Infection Microbiology, 2018, 8: 4.
[2] ZHANG Ya w e i , WANG Qi, YIN Yuyao, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae infections: report from the China CRE network[J]. Antimicrobial Agents and Chemotherapy, 2018, 62(2): e01882-17.
[3] GU Danxia, DONG Ning, ZHENG Zhiwei, et al.A fatal outbreak of ST11 carbapenem-resistant hypervirulent Klebsiella pneumoniae in a Chinese hospital :a molecular epidemiological study[J]. The Lancet Infectious Diseases, 2018, 18(1): 37-46.
[4] ZHAO Yajie, ZHANG Xiucai, TORRES V V L,et al. An outbreak of carbapenem-resistant and hypervirulent Klebsiella pneumoniae in an intensive care unit of a major teaching hospital in Wenzhou,China[J]. Front Public Health, 2019 , 7:229.
[5] 全国细菌耐药监测网. 全国细菌耐药监测网2014 ～ 2019 年细菌耐药性监测报告[J]. 中国感染控制杂志, 2021, 20(1):15-30. China Antimicrobial Resistance Surveillance System. Antimicrobial resistance of bacteria: surveillance report from China Antimicrobial Resistance Surveillance System in 2014 ～ 2019 [J]. Chinese Journal of Infection Control, 2021, 20(1): 15-30.
[6] MENTASTI M, PRIME K, SANDS K, et al. Rapid detection of IMP, NDM, VIM, KPC and OXA-48-like carbapenemases from Enterobacteriales and Gramnegative non-fermenter bacteria by real-time PCR and melt-curve analysis[J]. European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38(11):2029-2036.
[7] ZHANG Yawei, ZHAO Chunjiang, WANG Qi, et al.High prevalence of hypervirulent Klebsiella pneumoniae infection in China: Geographic distribution, clinical characteristics, and antimicrobial resistance[J].Antimicrobial Agents and Chemotherapy, 2016, 60(10):6115-6120.
[8] RUSSO T, OLSON R, FANG Chitai, et al.Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K.pneumoniae[J]. Journal of Clinical Microbiology, 2018,56(9): e00776-18.
[9] 全国细菌耐药监测网. 全国细菌耐药监测网2014 ～ 2019 年耐碳青霉烯类肺炎克雷伯菌流行病学变迁[J]. 中国感染控制杂志, 2021, 20(2): 175-179. China Antimicrobial Resistance Surveillance System. Epidemiological change in carbapenem-resistant Klebsiella pneumoniae:surveillance report from China Antimicrobial Resistance Surveillance in 2014 ～ 2019[J]. Chinese Journal of Infection Control, 2021, 20(2):175-179.
[10] XU Liangfei, SUN Xiaoxi, MA Xiaoling. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae[J]. Annals of Clinical Microbiology and Antimicrobials, 2017, 16(1): 18.
[11] LI Meiling, WANG Xiaoli, WANG Jiahui, et al.Infection-prevention and control interventions to reduce colonisation and infection of intensive care unitacquired carbapenem-resistant Klebsiella pneumoniae:a 4-year quasi-experimental before-and-after study[J].Antimicrobial Resistance and Infection Control, 2019,8(1): 8.
[12] 邓文喻, 陈国洋, 麦荣嘉, 等．婴幼儿肺泡灌洗液中肺炎克雷伯菌对β-内酰胺类抗生素的耐药变迁[J].现代检验医学杂志, 2020, 35(1):75-78. DENG Wenyu, CHEN Guoyang, MAI Rongjia, et al. Changes of resistance of Klebsiella pneumoniae to beta-lactam antibiotics in alveolar lavage fluid of infants [J]. Journal of Modern Laboratory Medicine,2020, 35(1):75-78.
[13] SHIELDS R K, CLANCY C J, PRESS E G, et al.Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae[J].Antimicrobial Agents and Chemotherapy, 2016, 60(5):3187-3192.
[14] 张敬霞, 贾天野, 张树永, 等. 头孢他啶/ 阿维巴坦对耐碳青霉烯肠杆菌科细菌的体外抗菌活性研究[J]. 中国抗生素杂志, 2018, 43(9): 1109-1116. ZHANG Jingxia, JIA Tianye, ZHANG Shuyong, et al.Study on in vitro antimicrobial activities of ceftazidime/avibactam to carbapenem-resistant Enterobacteriaceae [J].Chinese Journal of Antibiotics, 2018, 43(09): 1109-1116.
[15] KAZMIERCZAK K M, DE JONGE B, STONE G G,et al. In vitro activity of ceftazidime/avibactam against isolates of Enterobacteriaceae collected in European countries: INFORM global surveillance 2012-15[J].The Journal of Antimicrobial Chemotherapy, 2018,73(10): 2782-2788.
[16] 周琴, 杨向贵, 王丹, 等. 头孢他啶/ 阿维巴坦对耐碳青霉烯类肺炎克雷伯菌的体外抗菌活性分析[J].华西医学, 2020, 35(8): 918-923. ZHOU Qin, YANG Xianggui, WANG Dan, et al.Analysis of antibacterial activity of ceftazidime/avibactam against carbapenem resistant Klebsiella pneumoniae in vitro [J]. West China Medical Journal,2020, 35(8): 918-923.
[17] HANSEN G T. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other Gram-Negative bacteria[J].Infectious Diseases and Therapy, 2021, 10(1): 75-92.
[18] ZHANG Rong, LIU Lizhang, ZHOU Hongwei, et al. Nationwide surveillance of clinical carbapenemresistant Enterobacteriaceae (CRE) strains in China[J].EBioMedicine, 2017, 19: 98-106.
[19] 王青, 李耘, 郑波．中国2017 ～ 2018 年耐碳青霉烯类肺炎克雷伯菌药物敏感性及耐药基因分析[J].中国感染控制杂志, 2021, 20(5): 437-442. WANG Qing, LI Yun, ZHENG Bo. Antimicrobial susceptibility and resistance genes of carbapenemresistant Klebsiella pneumoniae in China from 2017 to 2018 [J]. Chinese Journal of Infection Control, 2021,20(5): 437-442.
[20] VENA A, CASTALDO N, BASSETTI M. The role of new β-lactamase inhibitors in gram-negative infections[J]. Current Opinion in Infectious Diseases,2019, 32(6): 638-646.
[21] CHOBY J E, HOWARD-ANDERSON J, WEISS D S. Hypervirulent Klebsiella pneumoniae -clinical and molecular perspectives[J]. Journal of Internal Medicine,2020, 287(3): 283-300.
[22] RUSSO T A, OLSON R, MACDONALD U, et al.Aerobactin mediates virulence and accounts for increased siderophore production under Iron-Limiting conditions by hypervirulent (hypermucoviscous) Klebsiella pneumoniae[J]. Infection and Immunity,2014, 82(6): 2356-2367.
[23] RUSSO T A, OLSON R, MACDONALD U, et al.Aerobactin, but not yersiniabactin, salmochelin,or enterobactin, enables the growth/survival of hypervirulent (hypermucoviscous) Klebsiella pneumoniae Ex vivo and in vivo[J]. Infection and Immunity, 2015, 83(8): 3325-3333.
[24] LIU Chao, GUO Jun. Characteristics of ventilatorassociated pneumonia due to hypervirulent Klebsiella pneumoniae genotype in genetic background for the elderly in two tertiary hospitals in China[J].Antimicrobial Resistance and Infection Control, 2018,7(1): 95.
[25] 贾艳增, 马玉兰, 陈莹, 等. 碳青霉烯耐药高毒力肺炎克雷伯菌的实验室研究及与临床转归相关危险因素分析[J]. 现代检验医学杂志, 2021, 36(1): 112-115. JIA Yanzeng, MA Yulan, CHEN Ying, et al. Laboratory study and analysis of risk factors associated with clinical ouecomes of hypervirulent and carbapenemresistant Klebsiella pneumonia [J]. Journal of Modern Laboratory Medicine, 2021,36(1):112-115.
[26] JIN Longyang, LIU Yudong, JING Chendi, et al.Neutrophil extracellular traps (NETs)-mediated killing of carbapenem-resistant hypervirulent Klebsiella pneumoniae (CR-hvKP) are impaired in patients with diabetes mellitus[J]. Virulence, 2020, 11(1): 1122-1130.
[27] ZENG Lingyi, YANG Chengru, ZHANG Jisheng, et al. An outbreak of carbapenem-resistant Klebsiella pneumoniae in an intensive care unit of a major teaching hospital in chongqing, china[j]. Front Cell Infect Microbiol, 2021, 11: 656070.
[28] YU Fangyou, L? Jingnan, NIU Siqiang, et al. In vitro activity of ceftazidime-avibactam against carbapenemresistant and hypervirulent Klebsiella pneumoniae isolates[J]. Antimicrobial Agents and Chemotherapy,2018, 62(8): e01031-18.
相似文献/References:
[1]邵杰,杨玉东,朱红强,等.临床标本病原菌检测及耐药数据的回顾性分析研究[J].现代检验医学杂志,2015,30(06):113.[doi:10.3969/j.issn.1671-7414.2015.06.034]
SHAO Jie,YANG Yu-dong,ZHU Hong-qiang,et al.Retrospective Analysis of the Pathogens
and Drug Resistance of Clinical Specimens[J].Journal of Modern Laboratory Medicine,2015,30(04):113.[doi:10.3969/j.issn.1671-7414.2015.06.034]
[2]张 丽,齐 军,吴宗勇,等.耐碳青霉烯类肺炎克雷伯菌临床分离株中喹诺酮类及16SrRNA甲基化酶基因的检测[J].现代检验医学杂志,2018,33(05):27.[doi:10.3969/j.issn.1671-7414.2018.05.008]
ZHANG Li,QI Jun,WU Zong-yong,et al.Detection of Quinolone and 16SrRNA Methyltransferasegene of Clinical Isolated Carbapenem-Resistant Klebsiella Pneumoniae[J].Journal of Modern Laboratory Medicine,2018,33(04):27.[doi:10.3969/j.issn.1671-7414.2018.05.008]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of
Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]刘 伟,白 婧,尹可欣,等.2015~2019年北京市海淀区食源性腹泻患者致泻大肠埃希氏菌型别分布和耐药性分析[J].现代检验医学杂志,2021,36(06):188.[doi:10.3969/j.issn.1671-7414.2021.06.041]
LIU Wei,BAI Jing,YIN Ke-xin,et al.Type Distribution and Drug Resistance of Diarrheagenic Escherichia coli in Patients with Foodborne Diarrhea in Haidian District, Beijing, 2015~2019[J].Journal of Modern Laboratory Medicine,2021,36(04):188.[doi:10.3969/j.issn.1671-7414.2021.06.041]
[5]赵 颖,李 茁,张 鹏,等.2014~2020年陕西省人民医院耐碳青霉烯类肺炎克雷伯菌检出率与同期抗生素暴露及相关危险因素分析[J].现代检验医学杂志,2021,36(06):192.[doi:10.3969/j.issn.1671-7414.2021.06.042]
ZHAO Ying,LI Zhuo,ZHANG Peng,et al.Exploration of Risk Factors and the Antimicrobial Exposure Associated with Increased Detection of Carbapenem-resistant Klebsiella Pneumoniae in Shaanxi Provincial People’s Hospital from 2014 to 2020[J].Journal of Modern Laboratory Medicine,2021,36(04):192.[doi:10.3969/j.issn.1671-7414.2021.06.042]
[6]郑 茂a,陈宗耀a,鄂建飞a,等.高毒力肺炎克雷伯菌对碳青霉烯类耐药机制研究进展[J].现代检验医学杂志,2022,37(01):207.[doi:10.3969/j.issn.1671-7414.2022.01.043]
ZHENG Maoa,CHEN Zong-yaoa,E Jian-feia,et al.Research Progress on the Mechanism of Hypervirulent Klebsiella Pneumoniae Resistance to Carbapenems[J].Journal of Modern Laboratory Medicine,2022,37(04):207.[doi:10.3969/j.issn.1671-7414.2022.01.043]
[7]李阳昱,杨 旭,陈孝红,等.耐碳青霉烯类肺炎克雷伯菌的耐药机制和治疗策略研究进展[J].现代检验医学杂志,2023,38(06):191.[doi:10.3969/j.issn.1671-7414.2023.06.035]
LI Yangyu,YANG Xu,CHEN Xiaohong,et al.Research Progress on Resistance Mechanisms and Therapy Strategies of Carbapenem Resistant Klebsiella Pneumonia[J].Journal of Modern Laboratory Medicine,2023,38(04):191.[doi:10.3969/j.issn.1671-7414.2023.06.035]